Meeting
2024 ASCO Gastrointestinal Cancers Symposium
First report of the randomized phase III study of bi-weekly trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) vs. FTD/TPI monotherapy for chemorefractory metastatic colorectal cancer (mCRC): JCOG2014 (ROBiTS).
Authors
Hironaga Satake
Department of Medical Oncology, Kochi Medical School, Nankoku-City, Japan
Hironaga Satake , Kentaro Yamazaki , Yusuke Suwa , Takahiro Tsushima , Yasunobu Ishizuka , Shogen Boku , Atsuo Takashima , Toshifumi Yamaguchi , Masako Asayama , Mitsuru Yokota , Koji Numata , Takashi Ohta , Hisateru Yasui , Yosuke Kito , Yasumasa Takii , Ryo Kitabayashi , Yusuke Sano , Haruhiko Fukuda , Tetsuya Hamaguchi , Yukihide Kanemitsu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
jRCTs031210544
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 118)
DOI
10.1200/JCO.2024.42.3_suppl.118
Abstract #
118
Poster Bd #
H3
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
ALTER-C-001: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC—A single-arm, multicenter, phase Ⅱ clinical trial.
First Author: Jin Yan
Poster
2019 ASCO Annual Meeting
A phase IIb study of ramucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic, chemotherapy refractory colorectal cancer patients: The RAMTAS trial of the German AIO (KRK-0316).
First Author: Stefan Kasper
Poster
2016 ASCO Annual Meeting
Sorafenib (Soraf) and irinotecan (Iri) combination for pretreated RAS-mutated metastatic colorectal cancer (mCRC) patients: A multicentre randomized phase II trial (NEXIRI 2-PRODIGE 27).
First Author: Emmanuelle Samalin
Poster
2012 Gastrointestinal Cancers Symposium
Efficacy of vemurafenib (V) a selective V600EBRAF inhibitor, as monotherapy or in combination with erlotinib (Erl) or erbitux (Erb) and irinotecan (Iri) doublets and triplets in a colorectal cancer (CRC) xenograft model.
First Author: Brian Higgins